Navigation Links
Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
Date:9/17/2007

Collaboration validates unique HIV assay system that identifies potential

tRNA inhibitors

CARY, N.C. and BIRMINGHAM, Ala., Sept. 17 /PRNewswire-USNewswire/ -- Trana Discovery, a drug discovery company, today announced the development of a high throughput screening (HTS) assay for the identification of new compounds for the treatment of HIV. The HTS assay was developed in collaboration with Southern Research Institute, a research organization that conducts basic and applied preclinical drug research. This new assay gives pharmaceutical companies the ability to rapidly and efficiently screen vast libraries of compounds in order to identify those that interrupt the lifecycle of HIV through a novel mechanism of action -- the inhibition of transfer RNA (tRNA). This technology has the potential to discover new classes of medicines for the treatment of HIV that may overcome resistance mechanisms associated with current therapies.

To date in the U.S., about 30 drugs -- as single agents or as combination products -- for the treatment of HIV infections have been introduced by more than ten different companies. But collectively, these agents represent only five different classes working at just four different sites of action in the HIV replicative cycle. And despite the enhanced potency of the more recently introduced products, resistance continues to be a major challenge for managing patients with HIV.

There remains an unexploited target for antiretroviral drugs -- the disruption of human transfer RNA (tRNA) use by the virus during HIV replication. But until recently, several barriers, including the stability of the RNA-RNA binding during experimentation, had prevented exploration of tRNA as a drug target. Working in collaboration with Southern Research, Trana Discovery refined their technology to overcome those barriers in a HTS format, thus opening the way to discovery and development of HIV drugs that work by means of
'/>"/>

SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
2. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
3. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
4. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
7. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
8. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
9. Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies Annual Meeting
10. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
11. Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... May 23, 2012 Medical Tactile, Inc. (MTI), ... Incorporated, today announced that they have developed a pre-commercial ... sensor technology for breast cancer screening.  ... Komen Foundation, 1.6 million women worldwide were diagnosed with ... the disease. Although early detection is the best means ...
(Date:5/23/2012)... Kraton Performance Polymers, Inc. (NYSE: "KRA"), ... or SBCs , and PolyOne Distribution, a ... and solutions, announce the execution of a distribution ... PolyOne product line. "Kraton Polymers ... IR products due to their deep knowledge about ...
(Date:5/23/2012)... 2012  Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... for its U.S. phase 2 clinical trial, T ... G reater E fficacy T rial ... in patients with non-tuberculous mycobacterial (NTM) lung disease. ... to support current NTM treatment recommendations, and no new ...
Breaking Medicine Technology:Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 2Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 3Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 4Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 2Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5Resource savvy communities generate healthy sustainable changes 15181 1Resource savvy communities generate healthy sustainable changes 15181 2Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 1Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 2U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 1U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 2
... Type 2 Diabetes Using Emisphere,s Eligen(R) ... ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) today announced findings from a ... study used a delivery-agent-based approach using Emisphere,s Eligen(R),technology, and was conducted ...
... meets primary endpoints in ENGAGE Trial, KENILWORTH, ... ) announced today that corifollitropin alfa, its,experimental, sustained ... Phase III ENGAGE trial, according to data presented ... of the,European Society of Human Reproduction and Embryology ...
Other Medicine Technology:Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 2Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 3Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 2Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 3
(Date:5/23/2012)... proteins of the same kind, thereby triggering skeletal and ... researchers from the RUB Heart and Diabetes Center NRW ... in an interdisciplinary research project with colleagues from the ... the Journal of Biological Chemistry . , ... forms stabilizing filaments inside of the cells. Different mutations ...
(Date:5/23/2012)... FRANCISCO Prior treatment with inhaled corticosteroids in ... pneumonia (CAP) is associated with a lower incidence ... new study from researchers in Spain. , A ... (excess fluid that accumulates between the two pleural ... that arises as a result of a pneumonia, ...
(Date:5/22/2012)... Bend Research Inc., a leading independent ... expansion of its existing hot-melt extrusion (HME) ... Leistritz twin-screw mixer/extruder. , The 18mm ... 27mm Leistritz and 19mm Baker Perkins extruder ... high-shear wet-granulation capabilities. Many projects have been ...
(Date:5/22/2012)... The uproar that began last year when the U.S. ... longer offer regular prostate-cancer tests to healthy men continued ... report. Overall, they stuck to their guns, stating that ... cancer, the PSA test, causes more harm than good ... even dangerous, treatments. , But many people simply don,t ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- Two preliminary ... both the detection and treatment of pancreatic cancer. ... said they have fashioned a vaccine that, in early ... attacking cancer cells. The team -- from Case ... Cancer Center at University Hospitals Case Medical Center in ...
Breaking Medicine News(10 mins):Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Psychological Science explains uproar over prostate-cancer screenings 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4
... 18 Women,s, health and,environmental groups today called on ... wake of product tests released last week by the,Campaign ... an,independent lab, 61 percent (20 samples) contained detectable levels ... lipsticks with the highest lead,content were made by L,Oreal ...
... Decisions Network,(MDN) announces Food and Drug Administration 510(k) ... The MDN-CGS software is used,by hospital nurses to ... administered to patients with elevated levels of blood,glucose, ... to energy for survival. More and more ...
... to Reduce Number Denied by President, a Few in ... 2,000,children will join the ranks of the uninsured, adding ... public health insurance,according to new data released today by ... new analysis, American Families Face Harsh Reality: 2,000 Children,Join ...
... Mass., Oct. 18 Yankee Candle Company,Inc., the ... home fragrance, is,taking action in the fight against ... Logo: http://www.newscom.com/cgi-bin/prnh/20071018/NYTH093LOGO-b ) Yankee Candle ... breast,cancer awareness and research. The company is donating ...
... returning U.S. veterans , , THURSDAY, Oct. 18 (HealthDay News) ... when deciding how best to treat post-traumatic stress disorder ... of the data concludes. , The Institute of Medicine ... Affairs, which noted that about 12.6 percent of personnel ...
... Haas (NYSE:,ROH) announced today that it has ... used as a bonding alternative for pressure,sensitive ... like,door panels, interior pillars, instrument panels and ... before seen or thought possible,in an aqueous ...
Other Medicine News:Health News:Health Groups Call on Cosmetic Giant L'Oreal to Remove Lead From Lipstick 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day 2Health News:Yankee Candle Company Sheds Some Light In The Fight Against Breast Cancer 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 3Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 4Health News:New Water-Based Acrylic Pressure-Sensitive Adhesive Defeats Heat and Humidity Issue 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: